drugset
drugset / Trial / NCT05041543

Safety and Tolerability of NTX-101 in Korean Healthy Volunteers

NCT05041543 ↗

Phase 1 Completed 36 enrolled Pinotbio, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A double-blinded, placebo controlled, multiple dose, randomized, single site, phase 1 clinical trial to evaluate safety, tolerability, and pharmacokinetics of NTX-101 topical eye drop in Korean healthy volunteers

Timeline

Start
2021-03-02
Primary completion
2021-06-15
Completion
2021-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject NTX-101 Unknown — Topical

Indications

No indication recorded.